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Luciferase from Photinus pyralis is used widely as a reporter 
gene for in vivo bioluminescence imaging (BLI). Luciferase is 
an enzyme that can generate visible light through the oxidation 
of its substrate, d-luciferin, in the presence of oxygen and ATP.13 
This enzyme has been used to tag bacteria and mammalian 
cells, including tumor and immune cells, and in the generation 
of transgenic animals for in vivo studies of gene expression.24 
Typically the light transmitted through the animal’s tissues 
is detected by using charge-coupled–device (CCD) cameras 
to provide very sensitive in vivo measurements.4 To achieve 
quantitative measurements, the experimental conditions need 
to be considered carefully, with great attention to all parameters 
that might influence the reaction kinetics, light output, and 
consistency of the measurements.
Anesthesia is known to interfere with many physiologic 
processes, particularly cardiopulmonary functionality,20 which 
might influence substrate biodistribution. Consequently, 
anesthesia might affect photon emission in BLI experiments 
and needs to be evaluated carefully when planning the use of 
bioluminescence during in vivo experiments. Luciferase itself 
has served as a useful model to demonstrate a direct interac-
tion between general anesthetics and proteins at the molecular 
level,8-10,18,21,27 showing that a wide range of anesthetics at 
different potencies compete with d-luciferin for binding to the 
luciferase enzyme. The result of this interaction is an inhibition 
of the luciferase enzyme and a subsequent reduction of the total 
light output. The effects of anesthesia on the kinetics of the luci-
ferase reaction are not well characterized. After intraperitoneal 
injection of d-luciferin, the kinetic profile of the luciferase reac-
tion usually shows a gradual increase of photon emission, a peak 
with a stable plateau followed by a slow decrease in photon 
emission.16 The identification and repeatability of the stable 
plateau of light emission in any experimental condition is crucial 
for maintaining the quantitative nature of the measurements.
Here we describe the effects of 2 different anesthetics on the 
kinetic profile of the luciferase reaction. We used a transgenic 
rat model (PRL-Luc) that expresses luciferase under the control 
of the human prolactin promoter in the pituitary gland and 
various extrapituitary sites, such as bone and cartilage,26 and 
we performed in vivo intensity measurements by using both a 
custom fiber-optic probe that was implanted directly into the 
pituitary gland and a CCD camera. We show that the method 
of anesthesia has a marked effect in determining the rise time 
of light output in the luciferase reaction kinetics, and this ef-
fect directly influences the timing of image acquisition after 
substrate injection.
Materials and Methods
Rat model. The generation of PRL-Luc transgenic rats has 
been described previously.26 Briefly, the transgenic rats were 
generated by using a BAC clone that included approximately 
160 kb of the human prolactin genomic locus. The transgene was 
microinjected into the pronucleus of Fisher 344 rat zygotes. This 
study was completed under a UK Home Office License, after 
review by the local ethics committee. All rats were housed in-
dividually in a pathogen-free environment, given free access to 
water and standard commercial rat chow (Special Diet Service, 
Witham, UK), and maintained under controlled conditions of 
temperature (21 ± 1 °C) and humidity (50% ± 10%) under a 
12:12-h light:dark cycle. All of the procedures were terminal, 
and rats were euthanized by CO2 inhalation.
Probe construction. We constructed a fiber-optic device for 
light collection. The device consists of a 243-µm (outer diameter) 
silica fiber with a 200-µm core (Polymicro Technology, Phoenix 
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which the signal was greater than or equal to 95% of peak value. 
Data are presented as mean ± SE and were analyzed by using 
the Student t test (Prism, GraphPad Software, San Diego, CA). 
Significance was set as a P value of less than 0.05.
Results
A fiber-optic probe was placed on the dorsal surface of the 
pituitary of PRL-Luc transgenic rats by using stereotactic sur-
gery, and light-recording data were collected for as long as 1 h 
by using a photomultiplier tube (Figure 1 A). Luciferase reaction 
kinetics showed a marked difference between the 2 conditions 
described. Averaged data (Figure 1 B) show that the ketamine–
xylazine curve rises to peak value in 11 ± 1 min, whereas the 
isoflurane curve rises in 31 ± 2 min (P < 0.01).
These data were confirmed by using an alternative in vivo 
imaging method. Images of pituitary and bone–cartilage signals 
were collected by using a CCD camera (Figure 2 A). A clear shift 
and delay in the isoflurane kinetics is evident in the isoflurane 
curve compared with the ketamine–xylazine curve (Figure 2 
B), confirming the data obtained by using the fiber-optic probe 
in the pituitary. Quantification of the signal showed an 8-min 
difference between the anesthetics in reaching peak signal, with 
the ketamine–xylazine curve reaching it after 14 ± 1.7 min and 
the isoflurane curve after 22 ± 1 min (P < 0.05). Defining the 
plateau, as the time during which the signal is greater than or 
equal to 95% of peak value, the time needed to reach center pla-
teau is 16.33 ± 1.86 min for ketamine–xylazine and 22.67 ± 0.66 
min for isoflurane (P < 0.05). The length of the plateau is highly 
significantly (P = 0.0002) different between ketamine–xylazine 
and isoflurane (9.33 ± 0.33 and 15.33 ± 0.33 min, respectively). 
Both curves show a consistent decrease in signal in the last 30 
min of observation (33% for ketamine–xylazine and 35% for 
isoflurane), whereas the signal seems to be more stable when 
imaged with the fiber optics (Figure 1 B).
Table 1 shows how the light signal (expressed as percentage of 
peak signal), varies with the different anesthetics in the pituitary 
gland, at set time points after d-luciferin injections.
PRL-Luc transgenic rats also express luciferase in cartilage 
and bone tissues, and light emission was observed in the paws, 
ears, and tails of these rats (Figure 2 A). A less pronounced and 
nonsignificant time shift (2 min) was evident in data from the 
bone–cartilage imaging showing variability of luciferase kinetics 
in different organ and tissues. Peak signal was achieved after 
19 ± 3 min with ketamine–xylazine and after 21 ± 1.2 min with 
isoflurane. The time needed to reach the midpoint of the plateau 
differed numerically between the 2 anesthetics (21.33 ± 2.96 
for ketamine–xylazine and 23 ± 1.52 for isoflurane) as did the 
length of the plateau (10.33 ± 1.76 for ketamine–xylazine and 
13.0 ± 0.57 for isoflurane). In vivo optical imaging of bone and 
cartilage also showed a marked difference in absolute photon 
counts depending on whether the rats were anesthetized with 
ketamine–xylazine or isoflurane.
Discussion
The aim of the present study was to investigate the effects of 
2 different anesthetics on the kinetics of the luciferase reaction 
in vivo in rats. We used stereotaxis-assisted surgery to place 
a fiber optic directly on top of the pituitary of transgenic rats 
that express luciferase under the control of the human prolactin 
promoter.26 This method is sensitive, and the light detection 
is direct, spatially localized and not perturbed by tissue ab-
sorbance and scattering, as is the situation for whole-body in 
vivo imaging. The use of fiber optics in preclinical studies is 
AZ) and a numerical aperture of 0.21. To form a probe for light 
collection, one end of the fiber was threaded through a 50-mm 
surgical stainless steel tube with a 0.31-mm internal diameter 
and 0.56-mm outer diameter (24 gauge, Coopers Needle Works, 
Birmingham, UK). The fiber was secured inside the needle 
by using epoxy resin. The other end of the fiber carried an 
industry-standard SMA905 connector (Thorlabs, Newton, NJ). 
The probe was constructed to be approximately 1 m in length, 
with the fiber mechanically protected inside standard tubing 
(Thorlabs). A molded epoxy-resin plug sealed the end of the 
tubing to one end of the needle. The ends of the needle and the 
SMA connector were polished manually to give the fiber ends 
1 µm of surface roughness.
Fiber optic implantation and imaging modality. Female rats 
(age, 3 mo; weight, 200 g) were anesthetized by using 2 differ-
ent anesthesia regimens: isoflurane (Merial, Essex, UK) at 4% 
for induction, 2% to 2.5% for surgery, and 1.75% for imaging 
(n = 3 b) or ketamine (120 mg/kg IP; Vetalar, MA Holder, Kent, 
UK)–xylazine (10 mg/kg IP; Rompun, Bayer, Newbury, UK; n 
= 7). The top of the head was shaved and the rat was placed in 
a stereotaxis apparatus.11 The surface of the skull was exposed 
after incision and retraction of the overlaying skin and fascia. 
Bregma and lambda were identified, and a hole then was drilled 
through the skull at coordinates X = −1 and Y = −5.8 from 
bregma, which localize the target pituitary.23 The fiber-optic 
probe was lowered through the brain at coordinate Z = −9.8. 
We then injected a saturating solution of d-luciferin (50 mM d--
luciferin in physiologic saline; 180 mg/kg body weight IP) and 
imaging started (time 0). The rats were imaged continuously 
for as long as 1 h. Body temperature was measured by using 
a rectal probe and was maintained throughout the experiment 
by using a heating pad.
Data collection. Light gathered by the probe was cast onto 
a photomultiplier tube with self-contained electronics (Hama-
matsu Photonics, Hamamatsu City, Japan). The digital signal 
from this module representing the photon flux was integrated 
by using a Nexys2 FPGA module (Digilent, Pullman, WA) and 
recorded at 10-Hz intervals by using a laptop. All data record-
ing occurred in a dark environment to prevent stray light from 
affecting counts. In each case, we verified that that the count 
before d-luciferin injection was suitably low (less than 100 pho-
tons per second). Periodic inspections of the subject involved 
using room lights, causing artificial spikes in the data, which 
have been removed from all presented data.
In vivo optical imaging. Female transgenic rats were anesthe-
tized with either isoflurane (n = 3) or ketamine–xylazine (n = 3) 
as described earlier. Unshaved rats were laid on their backs on a 
heated pad, and photons were detected noninvasively by using 
a sensitive in vivo imaging system (IVIS Spectrum, Caliper Life 
Sciences, Hopkinton, MA). Rats were injected with a saturating 
luciferin solution (180 mg/kg IP, Biosynth, Staad, Switzerland) 
and laid on the heated surface of the instrument to keep the body 
temperature constant throughout the experiment. Images were 
collected in sequence every minute for 60 min. Images were 
taken by using the following parameters: exposure time, 10 s; 
binning, 8; no filter; f-stop ,1; and field of view, 19.6 cm. Regions 
of interest (ROI) were drawn around the pituitary signal and the 
bone–cartilage signal in the paws. Light output was measured 
as no. of photons/sec/cm2/sr. Images were analyzed by using 
Living Image software (Caliper Life Sciences). Body temperature 
was measured by using a rectal probe.
Data analysis. The rise time was defined as the time after 
injection during which the signal is rising prior to reaching the 
peak signal. The plateau time was defined as the time during 
jaalas11000168.indd   821 11/15/2012   9:13:11 AM
822
Vol 51, No 6
Journal of the American Association for Laboratory Animal Science
November 2012
ensure that images are quantitative and reproducible at different 
time points, our study shows that peak time under isoflurane 
is reached not earlier than 20 min after d-luciferin injection. In 
the current study, both fiber optic and in vivo optical imaging 
proved to be very reliable techniques in detecting the rise time 
of luciferase reaction kinetics but seem to show differences in 
signal decay. This effect can be explained with a temperature dif-
ference between the 2 imaging settings. During optical imaging 
with the CCD camera, we placed the rats in a closed imaging 
chamber on a heated pad, which maintained the animals’ body 
temperature at least 1 °C higher than that during fiber optic 
imaging. Moreover, consistent heat loss through the fiber-optic 
probe and the exposed skull in the stereotaxis setting should 
be anticipated and would reduce the rate of d-luciferin uptake 
and the speed of the luciferase reaction.
d-luciferin uptake kinetics and biodistribution can vary 
substantially between different organs,4 and the imaging con-
ditions should be validated carefully for the system of interest. 
To widen the applicability of our observation to the imaging 
of other organs and tissues, we studies the luciferase reaction 
kinetics in bone and cartilage tissues in the same rat model by 
using in vivo optical imaging. In these tissues, the time differ-
ence to reach peak light emission was much less pronounced 
(2 min) with the use of ketamine–xylazine or isoflurane. The 
anesthetic-associated difference was instead in the absolute pho-
ton emission, with signals being 3 times higher with isoflurane 
as with ketamine–xylazine. To explain these differences, the 
effects on the luciferase reaction of metabolic characteristics of 
the anesthetics and the hypoxic environment of cartilage need 
to be considered.25 Anesthetic agents and their carrier gases 
have well-known potential to alter tissue oxygenation.2,12,14 We 
therefore speculate that, given the highly hypoxic environment 
of cartilage, administration of isofluorane in oxygen would 
increase the oxygenation status of this tissue. Because the 
luciferase reaction is highly dependent on oxygen availability, 
isofluorane anesthesia could increase the total photon emis-
becoming quite widespread, reflecting the need of high resolu-
tion measurements and images that can detect changes at the 
molecular level in different tissues and organs.1,6,19 We have 
demonstrated that anesthesia has a profound effect on the 
profile of photon emission in rats, introducing variability in 
the rise time needed to reach peak value and have confirmed 
these findings by using a CCD camera. In addition to its effects 
on the rise time, anesthesia can modify the length of the stable 
plateau. These anesthesia-associated effects have important 
consequences regarding the reproducibility of quantitative 
measurements by BLI.
Quantitative BLI is a technique that has increasingly been 
used to study reporter gene activity in vivo. Most of the applica-
tions of BLI require precise quantitative measurements, which 
are achieved by closely controlling the experimental conditions 
and the multiple factors that alter photon emission.3,16 Anesthet-
ics have been recognized to interact at the molecular level with 
the luciferase enzyme and to compete with substrate binding to 
reduce total light production.9 We show here that the type of an-
esthetic can profoundly affect the time needed for the luciferase 
reaction to achieve peak emission and be maintained within a 
stable plateau. A 20-min difference has been observed in the 
time to peak signal between ketamine–xylazine and isoflurane 
anesthesia when fiber optics have been used to directly quantify 
light emission from the pituitary gland. This observation has 
been confirmed by using in vivo BLI, a less invasive imaging 
method, which has shown an 8-min difference in the rise time 
to peak signal. In addition, a significant difference was observed 
in the length of the stable plateau between the 2 anesthetics 
(9.33 ± 0.33 and 15.33 ± 0.33 min with ketamine–xylazine and 
isoflurane, respectively).
Isoflurane is administered by inhalation and is the most 
commonly used anesthetic for in vivo imaging because it is 
eliminated efficiently by the lungs allowing a rapid recovery. 
Because it is important to take bioluminescence images either 
at peak emission or during the plateau of photon emission to 
Figure 1. In vivo monitoring of bioluminescence from the pituitary of PRL-Luc transgenic rats by using fiber optics. (A) Experimental set-up. 
Rats were anesthetized by using 2 anesthetic regimes. A fiber-optic probe was inserted in the pituitary gland by using stereotaxis surgery. The 
light collected by the probe was transmitted onto a photomultiplier tube and analyzed on a laptop computer. All data recording were conducted 
in a dark environment. (B) Dynamic profiles of photon emission after anesthesia with ketamine–xylazine (K/X, red, n = 7) and isoflurane (Iso, 
blue, n = 3). Data are normalized to peak emission. Inset: raw, single-rat data
jaalas11000168.indd   822 11/15/2012   9:13:11 AM
823
Anesthesia affects luciferase reaction kinetics in vivo
could profoundly influence the interaction of the anesthetic 
with the luciferase enzyme.
Given that our model expresses luciferase under the control 
of the prolactin promoter and that anesthesia can influence 
prolactin secretion,7,17,22 we are aware that quantitative effects 
on the levels of luciferase expression could be dependent on the 
model. However, we believe that observations on the variations 
of time to reach peak level of photon emission or the length of 
the plateau are of general validity in making scientists aware of 
the importance of characterizing the chosen anesthetic in their 
experimental setting.
The results of the current study demonstrate a clear effect 
of anesthesia on luciferase reaction kinetics, which are also 
dependent on the site of imaging and strengthen the need for 
carefully choosing and testing the experimental conditions be-
fore any bioluminescence in vivo imaging analysis. This study 
identifies anesthesia as a parameter, which is critical for robust 
quantitative measurements during in vivo optical imaging. 
Our data also strengthen and confirm previous findings about 
the alteration of luciferase reaction kinetics under different an-
esthetic regimes.5,15 In light of our results, we strongly suggest 
the performance of a pilot study to determine the time kinetics 
of the luciferase reaction under the anesthetic regime chosen. 
sion in cartilage. This effect would be much less evident in the 
pituitary, where the levels of oxygenation already are elevated.
Of particular interest is the observation that the length of 
the stable plateau can vary considerably in different organs 
(pituitary and paws) under the 2 anesthetic regimes studied. A 
very significant difference in the plateau length was observed 
in the pituitary under ketamine–xylazine or isofluorane, but 
this difference is not significant when studying the paw signal. 
This observation highlights how the physiology of the tissue or 
organ of interest or secondary effects such as pH, O2, and CO2 
Figure 2. Optical imaging of luciferase kinetics in PRL-Luc transgenic rats expressing luciferase in the pituitary and bone–cartilage. (A) Image 
of a transgenic rat by using the IVIS spectrum. Pituitary and bone–cartilage (paw) regions of interest (ROI) have been marked and analyzed in 
regard to dynamic light emission. (B) Luciferase kinetics curve of pituitary light emission (ROI 1) after anesthesia with ketamine–xylazine (K/X, 
red; n = 3) and isoflurane (Iso, blue, n = 3). Data were not normalized. Inset: raw, single-rat data (C) Luciferase kinetics curve of bone–cartilage 
light emission (ROI 2) after anesthesia with ketamine–xylazine (K/X, red; n = 3) and isoflurane (Iso, blue; n = 3). Data were not normalized. 
Inset: raw, single-rat data
Table 1. Peak light signal (%, mean ± SE) during ketamine–xylazine (KX) 
or isoflurane anesthesia calculated by using either luciferase fiber-optic 












5 68 ± 14 37 ± 6 50 ± 6 23 ± 2
10 87 ± 10 65 ± 9 91 ± 3 73 ± 2
15 93 ± 4 77 ± 8 99 ± 1 95 ± 1
20 91 ± 5 85 ± 7 93 ± 1 99 ± 0
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This preliminary experiment might be achieved by acquiring 
sequential imaging after d-luciferin injection and determining 
the key window for stable measurements or the peak time for 
measurements, if the plateau time is too short.
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